Skip to main content


Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Does T2T Lead to Fewer Gout Flares?

Lancet Rheumatology reports that a treat-to-target (T2T) goal of average serum urate less than 6 mg/dL is associated with an absence of gout flares and a reduction in the number of flares in the next 12 months.

Fracture Risk with Osteoporosis Drug Holidays

While bisphosphonate drug holidays are recommended, there are few comparative studies.

Why Are Physicians Silent About Outrageous Drug Prices?

MedPage Today

This article was written by Dr. Milton Packer, who wonders why physicians are struggling to get their priorities straight.

The Overpricing of Drugs (1.14.2022)

Dr. Jack Cush reviews the news and journal articles from the past week on This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Hold Myophenolate or Not with COVID-19 Vaccination?

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

KEEPSaKe-1 Trial in Psoriatic Arthritis - IL-23 Inhibition is Effective

The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.

What Can JIA Patients Expect 18 Years In?

MedPage Today

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.

Biologic Treatment of Primary Sjogrens with Ianalumab

Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24.

BEAT LUPUS - Belimumab after Rituximab in SLE

A recent trial published in Annals of Internal Medicine analyzed the effects of B-cell depletion (rituximab) followed by B-cell suppression (belimumab) and showed effective lowering of anti-dsDNA titers and and fewer severe flare in patients with systemic lupus erythematosus (SLE).